Patients with advanced melanoma treated with surgical resection along with the drug ipilimumab had a 5-year melanoma-specific survival rate of 51% and a median overall survival duration of 60 months, according to researchers at the John Wayne Cancer Institute in Santa Monica, Calif. A 2012 study found a 7% survival rate for advanced melanoma patients treated with systemic medical therapy alone.

Full Story:
Dermatology News

Related Summaries